Global expansion With CE Mark approval for fibromyalgia across the EU and FDA clearance in the US, AVACEN Medical is positioned to expand into multinational markets and partner with distributors or healthcare networks to scale adoption of the AVACEN 100 in pain management and related circulatory therapies.

Strategic partnerships Recent collaboration with BrainIQ Health signals opportunities to co-market smarter wellness solutions and bundled therapies, suggesting potential channel partnerships with health tech, wellness platforms, and integrated care providers.

Diverse indications The broad therapeutic claims covering circulatory, neurological, lymphatic, and endocrinal dysfunction open doors to cross-selling to clinics treating fibromyalgia, arthritis, post-operative pain, sports medicine, and chronic pain management.

Public awareness Award recognition as Pain Management Technology Manufacturer of the Year and active participation in industry events enhances credibility for outreach to hospital systems, regional clinics, and specialty pain centers seeking noninvasive, drug-free pain solutions.

Growth indicators Revenue range and recent leadership appointments indicate a scaling phase with investment readiness, making AVACEN an attractive target for distributors, contract manufacturers, or strategic investors seeking growth in medical device pain management.